| Abstract | Thalidomide, lenalidomide and bortezomib have been approved for the treatment of relapsed or refractory multiple myeloma in the recent years. These agents are now being increasingly integrated into therapeutic regimens for newly diagnosed patients. First data are available on the promising activity of these novel agents in induction therapy, as well as maintenance treatment to improve outcome after stem cell transplantation. Whether these early results will lead to prolonged overall survival and thereby ultimately redefine the role of stem cell transplantation in first-line treatment of multiple myeloma will be one of the most important questions to be answered in the coming years.Bone Marrow Transplantation (2007) 40, 1129-1137; doi:10.1038/sj.bmt.1705829; published online 3 September 2007. |
| Authors | M S Raab, I Breitkreutz, K C Anderson
(Affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.)
|
| Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 40
Issue 12
Pg. 1129-37
(Dec 2007)
ISSN: 0268-3369 England |
| PMID | 17768392
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Antineoplastic Agents
- Boronic Acids
- Pyrazines
- bortezomib
- lenalidomide
- Thalidomide
|
| Topics |
- Antineoplastic Agents
(therapeutic use)
- Boronic Acids
- Drug Delivery Systems
(methods, trends)
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Multiple Myeloma
(therapy)
- Pyrazines
- Thalidomide
(analogs & derivatives)
- Treatment Outcome
|
